Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2
ERBB2 protein
Paget disease
extramammary
lapatinib
trastuzumab
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 Nov 2019
19 Nov 2019
Historique:
received:
10
07
2019
accepted:
24
09
2019
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
6
12
2019
Statut:
epublish
Résumé
Metastatic extramammary Paget's disease is a rare adenocarcinoma with poor prognosis. Several reports of human epidermal growth factor receptor 2 alterations point to its pathogenic role in the disease. However, the occurrence of treatment resistance to anti-HER2 therapy demand the need for further knowledge. We report of a patient with metastatic penoscrotal extramammary Paget's disease, with an
Identifiants
pubmed: 31803359
doi: 10.18632/oncotarget.27272
pii: 27272
pmc: PMC6877105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6647-6650Informations de copyright
Copyright: © 2019 Nordmann et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Références
Cancer Cell. 2016 Mar 14;29(3):255-269
pubmed: 26977878
Oncologist. 2014 Sep;19(9):1006-7
pubmed: 25085898
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Ann Oncol. 2017 Jan 1;28(1):128-135
pubmed: 28177460
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259-64
pubmed: 22949682
Oncologist. 2015 Jan;20(1):7-12
pubmed: 25480824
Br J Dermatol. 2013 Jun;168(6):1259-66
pubmed: 23360223
Cancer Cell. 2013 May 13;23(5):603-17
pubmed: 23680147
Br J Cancer. 2012 Aug 21;107(5):793-9
pubmed: 22850551
ESMO Open. 2016 Jan 18;1(1):e000003
pubmed: 27843579
Oncotarget. 2017 Nov 30;8(69):114371-114392
pubmed: 29371993